EGFR and non-small cell lung carcinoma: EGFR-TKI treatment given in first-line setting is now highly recommended for patients suffering advanced-stage EGFR-mutant NSCLC.[38] However, a significant shorter PFS was found in PD-L1 positive group when EGFR-TKIs were given as the first-line treatment, which should deserve more attention within our clinical practice.